20 Microns Analyst Review 2027: A P/E Under 10, a ₹100 Crore Capex Plan and Margins Under Pressure
- November 17, 2026
- Posted by: Kunal Singla
- Category: Market
20 Microns Stock Snapshot (16 Nov 2026 close)
- Current Market Price (CMP): ₹178.08
- 52-Week High / Low: ₹237.40 / ₹129.61
- Market Capitalisation: ₹629 crore
- P/E Ratio vs Industry P/E: 9.9 vs 9.3
- Latest Quarter (Q2 FY27) Revenue: ₹238 crore
- Latest Quarter (Q2 FY27) Net Profit: ₹13.7 crore
Quick Answer: The 20 Microns analyst review 2027 has no verified brokerage target to lean on, so it rests on reported results. Q2 FY27 revenue rose 3.2% to ₹238 crore, but net profit fell 21.4% to ₹13.7 crore as energy and freight costs pushed the operating margin down to 9.9% from 12.1%. The stock, at ₹178.08, trades at a P/E of about 9.9 with debt to equity of just 0.30. A ₹100 crore capex plan and a withdrawn FY27 guidance set up 2027 as a show-me year.
The 20 Microns analyst review 2027 covers a small company with an unusual mix: steady long-term growth, a low valuation and a recent profit dip. Readers searching for a 20 Microns share price target 2027 will find no verified brokerage call, but the reported numbers tell a clear story. Revenue grew in the September 2026 quarter, yet profit fell 21.4% because energy and freight costs climbed.
20 Microns processes natural minerals into fine, surface-treated powders and makes specialty chemicals used by paint, plastic, rubber, ceramic and personal care makers. Its profit nearly doubled from ₹34.7 crore in FY22 to ₹66.7 crore in FY26. The stock, at ₹178.08, is 25% below its 52-week high but 37% above its low.
Click Here – Get Free Investment Predictions
Where Brokerages Stand in the 20 Microns Analyst Review 2027
20 Microns has a market value of about ₹629 crore, and like many companies this size, it gets little formal brokerage coverage. We could not find a dated, named rating or target price from recent months that we could verify. We have not used unverified targets or consensus figures from aggregator sites.
| Brokerage | Rating | Target Price | Date |
|---|---|---|---|
| No verified recent coverage | – | – | As of November 2026 |
One outside check is available. CRISIL reaffirmed the company’s bank loan ratings, covering ₹117 crore of facilities, on 29 October 2026. That is a credit view, not an equity call, but it confirms lenders see the balance sheet as stable. The rest of this 20 Microns analyst review 2027 uses the company’s own filings.
Latest Quarter Breakdown in the 20 Microns Analyst Review 2027
| Metric | Q2 FY27 | Q2 FY26 | Change |
|---|---|---|---|
| Revenue from Operations | ₹238.2 crore | ₹230.8 crore | +3.2% |
| Net Profit | ₹13.7 crore | ₹17.4 crore | -21.4% |
| Operating Margin | 9.9% | 12.1% | -2.2 pts |
| H1 FY27 Net Profit | ₹31.4 crore | ₹34.2 crore | -8.3% |
The quarter brought a return to growth after a weak June quarter, when revenue had dipped about 1% year on year. The issue was cost. Management said higher energy and freight costs cut operating profit. Mineral processing uses a lot of power for grinding and drying, and finished goods travel long distances to customers, so both costs hit quickly.
Interestingly, gross margin improved by 79 basis points to 48.3% in the first half. The product mix and pricing are holding up. What changed is the cost of running plants and moving goods, which the 20 Microns analyst review 2027 treats as the key swing factor.
Inside the 20 Microns Business
For a 20 Microns share analysis, the business has two parts:
- Industrial micronised minerals: Natural minerals such as calcium carbonate, kaolin and talc are ground to very fine sizes and often surface-treated. These act as fillers and performance additives in paints, plastics, rubber, paper and ceramics.
- Specialty chemicals and functional additives: Higher-value products that improve properties such as strength, brightness or flow in a customer’s end product.
The company describes its range as surface-engineered mineral inputs and functional additives, with more than 250 specialised grades and over 1,000 customers. That spread means no single buyer or industry dominates. The move toward higher-value grades is what lifted gross margins over time.
The 20 Microns analyst review 2027 sees a model that is low-tech compared with pharma, but it rewards process know-how and reliable supply. Once a customer has approved a grade for its product, it rarely switches suppliers without reason.
Positive Triggers in the 20 Microns Analyst Review 2027
₹100 crore capex: The company is investing in new capacity, with about ₹17 crore planned for deployment in Q3 FY27. More capacity in high-value grades should support growth once running.
Paint and plastic demand: Housing, infrastructure and packaging drive demand for paints and plastics, which are the largest users of mineral fillers.
Import substitution: Indian makers of specialty additives are replacing imports in several categories.
Cost relief: Any easing in energy or freight costs would flow quickly into margins, given the stable gross margin.
What Could Go Wrong in the 20 Microns Analyst Review 2027
- Guidance withdrawn: Management withdrew its FY27 guidance after the March 2026 results, citing macroeconomic uncertainty.
- Energy and freight costs: These already cut margins by about two points in Q2 FY27.
- Customer cycles: A slowdown in paints, plastics or construction would reduce volumes.
- Liquidity: Daily trading volumes are thin, so prices can move sharply.
- No research coverage: Fewer outside analysts means less scrutiny of earnings.
Find Low P/E Small Caps on the Univest Screener
20 Microns Analyst Review 2027: Valuation Snapshot
| Parameter | Value |
|---|---|
| Market Cap | ₹629 crore |
| P/E (TTM) / Industry P/E | 9.9 / 9.3 |
| Price to Book | 1.23 |
| Return on Equity | 12.5% |
| Debt to Equity | 0.30 |
| Dividend Yield | 0.70% |
| FY26 Revenue / Net Profit | ₹960 crore / ₹66.7 crore |
| FY26 Operating Cash Flow | ₹103.6 crore |
In the 20 Microns analyst review 2027, a P/E ratio under 10 and a price to book of 1.23 are low for a company that has grown profit every year since FY22. Debt to equity has fallen from 0.49 to about 0.30 over the same period. Operating cash flow of ₹103.6 crore in FY26 was the best in five years, which helps fund the capex without much new borrowing. Small caps of this kind often trade at a discount to the names in the Nifty Smallcap 100 because of thin liquidity.
Ownership Pattern Over Five Quarters
| Holder | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|---|
| Promoters | 45.04% | 45.04% | 45.04% | 45.04% | 45.04% |
| FIIs | 0.26% | 0.26% | 0.41% | 0.41% | 1.03% |
| DIIs | 0.17% | 0.07% | 0.11% | 0.07% | 0.07% |
| Public | 54.52% | 54.63% | 54.44% | 54.48% | 53.86% |
Promoter holding is steady at 45.04%, led by Ionix Advanced Materials with 24.56%. Foreign investors quadrupled their small stake to 1.03% over the year. Domestic institutions hold almost nothing. For the 20 Microns analyst review 2027, any mutual fund entry would be a meaningful signal.
Next Catalysts in the 20 Microns Analyst Review 2027
- Q3 FY27 results (around early February 2027): Whether operating margins recover toward 12%.
- Capex progress: Spending and commissioning dates for the ₹100 crore plan.
- Energy and freight costs: The main margin driver in the near term.
- Fresh guidance: Whether management reinstates annual targets.
- Institutional buying: Any first entry by domestic funds.
Where the 20 Microns Analyst Review 2027 Leaves Investors
The 20 Microns analyst review 2027 points to a steady compounder caught in a cost squeeze. Five years of profit growth, falling debt, strong cash flow and a P/E under 10 are clear positives. The Q2 FY27 results showed the weak spot: energy and freight costs can quickly erode margins.
With no verified brokerage targets, the 20 Microns stock outlook 2027 depends on two things the company can show in its own numbers: margin recovery and on-time capex. Both will be visible over the next two or three quarters.
Disclaimer: This article is for educational and informational purposes only and is not investment advice or a recommendation to buy, sell or hold any security. Brokerage ratings and target prices quoted here are opinions of third-party research houses; Univest does not endorse them and gives no buy or sell call. Investments in the securities market are subject to market risks. Read all related documents carefully before investing. Research Analyst: Uniresearch Global Pvt. Ltd., SEBI Registration No. INH000013776.
Frequently Asked Questions
What is the short version of the 20 Microns analyst review 2027?
The 20 Microns analyst review 2027 shows a profitable small cap with no verified brokerage coverage. Q2 FY27 revenue rose 3.2% to ₹238 crore, while profit fell 21.4% to ₹13.7 crore on higher costs. The stock trades at a P/E of about 9.9. Debt to equity is low at 0.30.
Is there a 20 Microns share price target 2027 from brokerages?
We could not find a dated, named brokerage target in recent months that we could verify. The company’s market value is about ₹629 crore, and stocks this size often lack formal coverage. CRISIL reaffirmed its bank loan ratings in October 2026, which is a credit view rather than a price target. Investors can track reported margins and capex instead.
Which Q2 FY27 numbers matter in the 20 Microns analyst review 2027?
Revenue from operations grew 3.2% to ₹238.2 crore. Net profit fell 21.4% to ₹13.7 crore, and the operating margin dropped to 9.9% from 12.1%. For the first half, profit fell 8.3% to ₹31.4 crore. Gross margin still improved 79 basis points to 48.3%.
Why does the 20 Microns analyst review 2027 flag a Q2 profit fall?
Management said higher energy and freight costs reduced operating profit. Mineral grinding and drying use a lot of power, and products travel long distances to customers. Gross margins actually improved, so pricing and product mix held up. The pressure came from running and shipping costs.
What products does the 20 Microns analyst review 2027 cover?
The company processes minerals such as calcium carbonate, kaolin and talc into fine powders used in paints, plastics, rubber, paper and ceramics. It also makes specialty chemicals and functional additives. It offers more than 250 specialised grades to over 1,000 customers. FY26 revenue was about ₹960 crore.
What could hurt the stock, according to the 20 Microns analyst review 2027?
Management withdrew its FY27 guidance, citing macroeconomic uncertainty. Energy and freight costs remain the main threat to margins. Demand depends on paints, plastics and construction, which are cyclical. Thin trading volumes can also cause sharp price swings.
What should investors watch in the 20 Microns stock outlook 2027?
The Q3 FY27 results, due around early February 2027, will show whether margins recover toward 12%. Progress on the ₹100 crore capex plan, with about ₹17 crore planned for Q3, is another marker. Any reinstated guidance would add clarity. First buying by domestic funds would also stand out in the 20 Microns analyst review 2027.